Heart Failure Drugs Market to Reach USD 21.4 Billion by 2035

According to analysts at Vantage Market Research, the Global Heart Failure Drugs Market size is worth USD 8.6 Billion in 2024 and is projected to reach USD 21.4 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 12.1% from 2024 to 2035. Key trends of market includegrowing use of novel therapies, personalized medicine approaches, increased adoption of advanced drug classes like SGLT2 inhibitors, and expanding clinical research and innovation.

Market Overview

The increasing prevalence of heart failure is a significant driver in the heart failure drugs market industry, as it leads to a higher demand for effective treatments. The global rise in heart failure cases can be attributed to various factors, such as an aging population, lifestyle-related risk factors including obesity, hypertension, and diabetes, and the growing incidence of cardiovascular diseases. As people age, the heart becomes more vulnerable to conditions like heart failure, creating a larger patient pool that requires continuous management through pharmacological interventions. Additionally, the prevalence of comorbidities such as diabetes and high blood pressure further exacerbates heart failure, leading to a greater need for specialized drugs. The rising burden of heart failure is prompting healthcare systems worldwide to invest in better management and treatment strategies, which includes the development and adoption of novel drug therapies.

Rising awareness and early diagnosis are key drivers, as they contribute to improved patient outcomes and a higher demand for effective treatments. Increased public and healthcare professional awareness about heart failure symptoms, risk factors, and the importance of early intervention has led to earlier detection of the condition. Early diagnosis enables timely initiation of therapies, preventing disease progression and improving long-term health outcomes. With the growing availability of diagnostic tools, such as biomarkers and imaging technologies, healthcare providers can now identify heart failure at earlier stages, even before symptoms become severe.

Bayer launches novel heart failure drug Verquvo for Rs 127 a pill

• In September 2022, Bayer launched a novel heart failure drug  in India that it has co-developed with Merck at one-fifteenth of the global price at Rs 127 per pill. It’s a one pill a day therapy. The drug named Verquvo (vericiguat) is the first novel treatment approved to reduce the risk of cardiovascular deaths and repeated hospitalisation among worsening heart failure patients, the company said

Key Takeaways from the Report

• In 2024, North America dominated the market industry with largest market share of 36.20%. Market is driven by a high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and strong adoption of innovative therapies
• In 2024, based on the Drugs Type, the ACE Inhibitors category accounted largest share in market. ACE inhibitors are mainly used in the treatment of heart failure
• In 2024, based on the End User, the Hospitals category accounted for significant market share of 56.70%. The segment is driven by presence of specialized cardiology departments and intensive care units (ICUs) in hospitals is addressing complex cases

Top Companies

• Amgen
• Astrazeneca
• Bayer AG
• Novartis AG
• Gilead
• Pfizer Inc
• Teva Pharmaceuticals
• Cardior Pharmaceuticals GmbH
• GlaxoSmithKline
• Bristol-Myers Squibb Company
• Eli Lilly and Company

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline

• In January 2023, AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease